Table 2 Treatment-related adverse events occurring in ≥10% of patients
Adverse event | All grades a | Apatinib (n = 25), n (%) | ||
|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | ||
Fatigue | 22 (88) | 13 (52) | 7 (28) | 2 (8) |
Hand-foot syndrome | 20 (80) | 5 (20) | 10 (40) | 5 (20) |
AST increased | 17 (68) | 16 (64) | 1 (4) | |
Proteinuria | 16 (64) | 7 (28) | 6 (24) | 3 (12) |
Thrombocytopenia | 16 (64) | 13 (52) | 3 (12) | |
Diarrhea | 16 (64) | 9 (36) | 7 (28) | |
Headache | 15 (60) | 13 (52) | 2 (8) | |
Nausea | 14 (56) | 10 (40) | 3 (12) | 1 (4) |
Decreased appetite | 14 (56) | 11 (44) | 3 (12) | |
Dizziness | 14 (56) | 13 (52) | 1 (4) | |
Hypertension | 13 (52) | 5 (20) | 8 (32) | |
Urine occult blood | 12 (48) | 11 (44) | 1 (4) | |
Anemia | 12 (48) | 7 (28) | 5 (20) | |
ALT increased | 11 (44) | 9 (36) | 2 (8) | |
Mucositis oral | 10 (40) | 5 (20) | 4 (16) | 1 (4) |
WBC decreased | 10 (40) | 6 (24) | 4 (16) | |
Blood bilirubin increased | 10 (40) | 7 (28) | 3 (12) | |
Hyponatremia | 10 (40) | 10 (40) | ||
Vomiting | 10 (40) | 7 (28) | 2 (8) | 1 (4) |
Neutrophilic granuloaytopenia | 9 (36) | 5 (20) | 3 (12) | 1 (4) |
Cough | 8 (32) | 8 (32) | ||
Creatinine increased | 7 (28) | 5 (20) | 2 (8) | |
Hypochloremia | 5 (20) | 5 (20) | ||
Lymphocytopenia | 5 (20) | 1 (4) | 1 (4) | 3 (12) |
Weight loss | 5 (20) | 5 (20) | ||
Chest distress | 5 (20) | 4 (16) | 1 (4) | |
Hoarseness | 4 (16) | 4 (16) | ||
Hypertriglyceridemia | 4 (16) | 4 (16) | ||
GGT increased | 3 (12) | 2 (8) | 1 (4) | |
Constipation | 3 (12) | 3 (12) | ||